TCMD Delivers 17% Revenue Growth, Boosts 2025 Outlook and Launches $25 Million Buyback
Strong Product Sales Drive Third-Quarter Upside
Tactile Systems Technology (NASDAQ: TCMD) turned in an impressive third quarter, posting 17% year-over-year revenue growth to $85.76 million and demonstrating its momentum as a leader in medical technology for chronic conditions. The gains were fueled by notable growth in both of the company’s main product categories—an 11% jump in lymphedema product sales and a remarkable 71% increase in airway clearance product sales. Gross margin improved to 76%, while net income surged to $8.21 million from $5.16 million a year earlier, and adjusted EBITDA leaped 34% to $14.42 million.
| Key Financial Metrics | Q3 2025 | Q3 2024 | % Change |
|---|---|---|---|
| Total Revenue | $85.76M | $73.09M | +17% |
| Gross Margin | 76% | 75% | +1pt |
| Net Income | $8.21M | $5.16M | +59% |
| Adjusted EBITDA | $14.42M | $10.72M | +34% |
Financial Health Strengthens as Debt Retired and Liquidity Maintained
TCMD exited the quarter with $65.97 million in cash and no debt, having fully repaid its $24 million term loan during the quarter. Operating cash flow for the first nine months remained solid at $25.52 million. Despite the company returning cash to shareholders through share buybacks and debt repayment, its liquidity position remains robust, bolstered by an expanded revolving credit facility now totaling $40 million.
| Balance Sheet Highlights | 9/30/2025 | 12/31/2024 |
|---|---|---|
| Cash | $65.97M | $94.37M |
| Debt Outstanding | $0 | $26.18M |
| Total Assets | $259.18M | $297.92M |
Share Buyback Program and Guidance Upgrade Signal Confidence
TCMD’s board authorized a new $25 million share repurchase program—highlighting management’s belief in the company’s growth trajectory and strong cash generation. This buyback, set to run through late 2027, follows meaningful capital returns already underway this year and comes as diluted shares outstanding decline.
Reflecting its confidence, the company also raised its 2025 outlook, guiding for full-year revenue of $317–321 million (up 8–10%) and adjusted EBITDA of $38–39.5 million, a sharp improvement over previous forecasts. Guidance now assumes further sales strength and operational leverage into the end of the year.
| 2025 Guidance | Prior | Current | 2024 Actual |
|---|---|---|---|
| Total Revenue | $310–315M | $317–321M | $293.00M |
| Adjusted EBITDA | $33–35M | $38–39.5M | $37.05M |
Momentum Rooted in Product Leadership and Improved Execution
Behind the numbers, TCMD’s double-digit sales gains are propelled by a strategic focus on go-to-market execution and clinical innovation. Notably, the company showcased six-month data supporting its Flexitouch® Plus as a first-line lymphedema therapy for head and neck cancer patients, which may further strengthen its clinical edge. Product diversification is bearing fruit, as airway clearance sales now comprise 16% of quarterly revenue—up from 11% the year prior—helping offset concentrated risks and driving overall margin improvements.
| Q3 Product Revenue Mix | Q3 2025 | Q3 2024 |
|---|---|---|
| Lymphedema Products | $72.38M (84%) | $65.28M (89%) |
| Airway Clearance Products | $13.37M (16%) | $7.81M (11%) |
Key Takeaways: Positioned for Continued Outperformance
TCMD’s third quarter reflects operational strength and the impact of business transformation initiatives—translating to sustained growth, robust profitability, and strong balance sheet discipline. The increased share buyback and guidance hike further highlight management’s conviction. As the company closes 2025, investors may want to monitor execution on further revenue diversification and capital deployment, as well as progress on margin expansion into 2026 and beyond. For those following medical technology growth stories, TCMD is demonstrating how product innovation, focused execution, and shareholder returns can reinforce one another in today’s healthcare landscape.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI